 PENNINGTON, N.J. and SAN DIEGO, Nov. 9, 2020 PRNewswire -- OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec today announced new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVOTM tavokinogene telseplasmid, a... 